Company Description
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally.
The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
The Salix segment provides gastroenterology products. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products.
The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; dermatology products; generic pharmaceutical products; and dentistry products.
The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products.
The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018.
Bausch Health Companies Inc. is headquartered in Laval, Canada.
| Country | Canada |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 20,700 |
| CEO | Thomas Appio |
Contact Details
Address: 2150 St. ElzEar Boulevard West Laval, QC H7L 4A8 Canada | |
| Phone | 514 744 6792 |
| Website | bauschhealth.com |
Stock Details
| Ticker Symbol | BHC |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000885590 |
| CUSIP Number | 071734107 |
| ISIN Number | CA0717341071 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas J. Appio | Chief Executive Officer and Director |
| Jean-Jacques Charhon | Executive Vice President and Chief Financial Officer |
| Seana Carson | Executive Vice President and General Counsel |
| Aimee J. Lenar | Executive Vice President of US Pharma |
| Mirza Dautbegovic | Executive Vice President and Chief Operating Officer |
| Garen Sarafian | Vice President and Head of Investor Relations |
| Kathleen Fitzpatrick | Executive Vice President and Chief Human Resources and Communications Officer |
| Cees Heiman | Senior Vice President of Europe and Canada |
| Donald Pearl | Senior Vice President of Ortho Dermatologics |
| Jiny Kim M.B.A. | Senior Vice President of Solta Medical |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 22, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 17, 2025 | CERT | Certification by an exchange approving securities for listing |
| Apr 15, 2025 | 8-K | Current Report |
| Apr 15, 2025 | 8-A12B | Registration of securities |
| Apr 9, 2025 | 8-K | Current Report |
| Apr 7, 2025 | SCHEDULE 13D | Filing |
| Apr 2, 2025 | ARS | Filing |
| Apr 2, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 2, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 25, 2025 | 8-K | Current Report |